Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.

Abstract

Increasing evidence suggests that angiotensin-converting enzyme (ACE) inhibitors can increase vascular nitric oxide (NO) production. Recent studies have found that combined inhibition of ACE and neutral endopeptidase (NEP) may have a greater beneficial effect in the treatment of heart failure than inhibition of ACE alone. Amlodipine, a calcium channel antagonist, has also been reported to have a favorable effect in the treatment of patients with cardiac dysfunction. The purpose of this study was to determine whether and the extent to which all of these agents used in the treatment of heart failure stimulate vascular NO production. Heart failure was induced by rapid ventricular pacing in conscious dogs. Coronary microvessels were isolated from normal and failing dog hearts. Nitrite, the stable metabolite of NO, was measured by the Griess reaction. ACE and NEP inhibitors and amlodipine significantly increased nitrite production from coronary microvessels in both normal and failing dog hearts. However, nitrite release was reduced after heart failure. For instance, the highest concentration of enalaprilat, thiorphan, and amlodipine increased nitrite release from 85 +/- 4 to 156 +/- 9, 82 +/- 7 to 139 +/- 8, and 74 +/- 4 to 134 +/-10 pmol/mg (all *p <.01 versus control), respectively, in normal dog hearts. Nitrite release in response to the highest concentration of these two inhibitors and amlodipine was reduced by 41% and 31% and 32% (all #p <.01 versus normal), respectively, in microvessels after heart failure. The increase in nitrite induced by either ACE or NEP inhibitors or amlodipine was entirely abolished by Nw-nitro-L-arginine methyl ester, HOE 140 (a B2-kinin receptor antagonist), and dichloroisocoumarin (a serine protease inhibitor) in both groups. Our results indicate that: 1) there is an impaired endothelial NO production after pacing-induced heart failure; 2) both ACE and NEP are largely responsible for the metabolism of kinins and modulate canine coronary NO production in normal and failing heart; and 3) amlodipine releases NO even after heart failure and this may be partly responsible for the favorable effect of amlodipine in the treatment of heart failure. Thus, the restoration of reduced coronary vascular NO production may contribute to the beneficial effects of these agents in the treatment of heart failure.

• Authors: X Zhang, F A Recchia, R Bernstein, X Xu, A Nasjletti, T H Hintze
• Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 288 Issue 2 Pg. 742-51 (Feb 1999) ISSN: 0022-3565 [Print] United States
• PMID: 9918584 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Bradykinin Receptor Antagonists
• Cysteine Proteinase Inhibitors
• Glycopeptides
• Kininogens
• Kinins
• Protease Inhibitors
• Receptor, Bradykinin B2
• Vasodilator Agents
• Amlodipine
• Nitric Oxide
• ramiprilat
• Thiorphan
• Enalaprilat
• Ramipril
• phosphoramidon

Topics

• Amlodipine (pharmacology)
• Angiotensin-Converting Enzyme Inhibitors (pharmacology)
• Animals
• Bradykinin Receptor Antagonists
• Coronary Vessels (drug effects, metabolism)
• Cysteine Proteinase Inhibitors (pharmacology)
• Dogs
• Enalaprilat (pharmacology)
• Glycopeptides (pharmacology)
• Heart Failure (drug therapy, metabolism)
• Kininogens (pharmacology)
• Kinins (physiology)
• Nitric Oxide (biosynthesis, metabolism)
• Protease Inhibitors (pharmacology)
• Ramipril (analogs & derivatives, pharmacology)
• Receptor, Bradykinin B2
• Thiorphan (pharmacology)
• Vasodilator Agents (pharmacology)